Disclosures for "The Orexin 2 Receptor Agonist ALKS 2680 in Patients with Narcolepsy Type 1: An Initial Proof of Concept Phase 1b Study"
-
Prof. Grunstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly . Prof. Grunstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Apnimed. The institution of Prof. Grunstein has received research support from Alkermes. The institution of Prof. Grunstein has received research support from Eli Lilly.
-
Prof. Yee has nothing to disclose.
-
The institution of Dr. Chapman has received research support from American Academy of Sleep Medicine Foundation.
-
The institution of Dr. D'Rozario has received research support from Australian National Health and Medical Research Council. The institution of Dr. D'Rozario has received research support from Australian National Health and Medical Research Council. The institution of Dr. D'Rozario has received research support from Australian National Health and Medical Research Council. The institution of Dr. D'Rozario has received research support from Australian Government Medical Research Future Fund (MRFF) .
-
Dr. Hopkinson has received personal compensation for serving as an employee of Alkermes, Inc. An immediate family member of Dr. Hopkinson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for CoRA Consulting LLC. Dr. Hopkinson has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for Alberio. Dr. Hopkinson has stock in Alkermes, Inc.
-
Ms. Ramos has received personal compensation for serving as an employee of Alkermes.
-
Dr. Smith has received personal compensation for serving as an employee of Alkermes. Dr. Smith has stock in Alkermes.
-
Dr. Yagoda has received personal compensation for serving as an employee of Alkermes, Inc. Dr. Yagoda has stock in Alkermes, Inc.
-
Dr. Rege has stock in Alkermes. Dr. Rege has received intellectual property interests from a discovery or technology relating to health care.